Bryce Point Capital, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 22,686 shares of CRNX stock, worth $798,774. This represents 0.34% of its overall portfolio holdings.
Number of Shares
22,686Holding current value
$798,774% of portfolio
0.34%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
251Shares Held
86.3MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA9.09MShares$320 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$245 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$219 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$207 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$174 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...